Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
This article was originally published in The Pink Sheet Daily
Company expects data from three Phase III trials of mifepristone for PMD by year-end.
You may also be interested in...
Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.
Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.
The first of two trials testing rapid and sustained relief of psychotic features, designed under special protocol assessment with FDA, will begin "immediately," Corcept says. Corlux is expected to share the same safety restrictions as Mifeprex (RU-486).